March 7-9, 2018, Barcelona, Spain.
(BELG J MED ONCOL 2018:12(5):252–262)
By: W. Lybaert MD, T. Vandamme MD, G. Boons , T. Rondou , M. Twickler , I. Dero MD, F. van Fraeyenhove MD, L. De Backer , D. Van Genechten , M. Peeters MD, PhD
March 7-9, 2018, Barcelona, Spain.
(BELG J MED ONCOL 2018:12(5):252–262)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
